Based on this encouraging result, the phase 3 trial, HERTHENA-Lung02, currently examines patritumab deruxtecan versus platinum-based chemotherapy in patients with EGFR-mutated NSCLC after failure of EGFR TKIs (NCT05338970). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.